10 April 2024 - Public comment period now open until 7 May 2024; requests to make oral comment during public ...
26 March 2024 - Public comment period now open until 22 April 2024; requests to make oral comment during public ...
13 March 2024 - Independent appraisal committee voted that current evidence is not adequate to demonstrate a net health benefit ...
11 March 2024 - Independent appraisal committee voted that current evidence is not adequate to demonstrate superior net health benefits ...
7 March 2024 - Report will be subject of Midwest CEPAC meeting in September 2024; draft scoping document open to ...
1 February 2024 - Iptacopan and danicopan are two first in class agents that provide important health benefits, but there ...
25 January 2024 - KarXT has a novel mechanism of action, but there are significant uncertainties regarding long term efficacy ...
8 January 2024 - Independent appraisal committee voted that sotatercept demonstrated a net health benefit when compared to background therapy; ...
3 January 2024 - Report will be subject of CTAF meeting in July 2024; draft scoping document open to public ...
5 December 2023 - Public comment period now open until 9 January 2024; requests to make oral comment during public ...
28 November 2023 - Public comment period now open until 22 December 2023; requests to make oral comment during public meeting ...
21 November 2023 - Report will be subject of Midwest England CEPAC meeting in June 2024; draft scoping document open ...
14 November 2023 - Sotatercept added to background therapy appears to improve clinical outcomes, but there are uncertainties on long ...
1 November 2023 - Report will be subject of New England CEPAC meeting in May 2024; draft scoping document open ...
30 October 2023 - Independent appraisal committee voted that across all patient sub-populations, arsa-cel demonstrated a net health benefit when ...